Article

Vitamin D may lower colon cancer risk

Author(s):

People with higher levels of vitamin D in their blood may have a reduced risk of developing colorectal cancer, says research published this week online from the British Medical Journal. The study, part of the European Prospective Investigation into Cancer and Nutrition (EPIC), followed 1248 patients who developed colorectal cancer and compared them to 1248 patients who did not develop the cancer. Researchers found that patients who had the highest pre-cancer concentrations of vitamin D in their blood had about a 40 percent lower risk of developing colorectal cancer. In an interview with Reuters, EPIC investigator Mazda Jenab, PhD, said although the findings showed lower risk, "... this has to be balanced with caution regarding the potential toxic effects of too much vitamin D and the fact that very little is known about the association of vitamin D with either increased or reduced risk of other cancers." Jenab added, "the key take home message for colorectal cancer prevention is: stop smoking, increase physical activity, reduce obesity and abdominal fatness, and limit intakes of alcohol and red and processed meats."The EPIC study is one of the largest studies on how diet and health can impact the incidence of cancer. From 1992 to 1999, the EPIC study recruited over a half a million people in ten European countries to participate. Many findings have emerged from the study including research showing an increased risk of breast cancer in obese adults and research showing an increased risk of colon cancer in people who consume larger quantities of red and/or processed meats. For more information on the EPIC study, click here.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of doctor.
Image of man with black hair.
Picture of Dr. Pouneh Razavi
Richard Winneker gathers input from patients and researchers to shape MPN research, aiming to fund strategic projects for this population.
Dr. Curtiland Deville Jr. discusses the importance of crafting an individualized treatment plan for patients with prostate cancer.
Image of man.
Image of Crispino
Image of Dr. Reznick
Picture of Joy Anderson
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Related Content